PFIZER INC RECEIVES APPROVAL TO MARKET NEW ORAL COX-2 INHIBITOR BEXTRA (VALDECOXIB) IN EUROPE
Pfizer now offers the widest Cox-2 inhibitor portfolio
23-May-2003 -
Pfizer Inc has received approval to market Bextra® (valdecoxib) film coated tablets, the newest COX-2 selective inhibitor in its portfolio, in Europe for treatment of patients with pain and inflammation associated with osteoarthritis (OA), rheumatoid arthritis (RA) and primary dysmenorrhea ...
anti-inflammatory drugs
celecoxib
Iceland
+9